Sign In   |   Register
Resources & tools

 

Clinician's handbook - Targeting Familial Hypercholesterolaemia

Familial hypercholesterolaemia (FH) is the most common inherited metabolic condition, affecting about one in 200 people. As highlighted by the European Atherosclerosis Society (EAS) Consensus Panel, FH is seriously underdiagnosed and undertreated. This App, authored by members of the Panel, provides an important resource to tackle these issues. Detection, diagnosis, screening and management of FH are discussed, with emphasis on targeting children with FH to optimise benefit and reduce premature heart disease.

Supported by an Unrestricted Educational Grant from SANOFI and REGENERON.

App for iPad and iPhone

Diagnostic support tool - FH Score

Calculate your patient's  familial hypercholesterolaemia score

FH Score is a diagnosis support tool for use by healthcare professionals to support the diagnosis of adult patients at risk of heterozygous familial hypercholesterolaemia (HeFH), based on the EAS 2013 Consensus Statement on FH

FH Score is currently certified as a medical device for use in UK, Germany, Switzerland, France and Belgium, and is available in English, German, French, Italian and Dutch. It is intended to extend the certification for use to further EU countries in the near future.

FH Score


 

Dyslipidaemia management tutorial 2.0 - Diet at the heart of CVD prevention

This online tutorial focusses on the dietary management of dyslipidaemias, as an important part in the prevention of cardiovascular disease (CVD). It is a "refresher" course, for general practitioners (GPs) and healthcare professionals (HCPs) in primary care practices, to leverage existing knowledge in this key area. The 2.0 version has been updated and broadened to provide extensive information about the role of diet in dyslipidaemia management.

Diet at the heart of CVD prevention

 

Clinician's handbook - Lipoprotein(a), atherosclerosis & cardiovascular disease

This Handbook, authored by Professors Nordestgaard, Chapman and Ginsberg on behalf of the European Atherosclerosis Society Consensus Panel, provides a unique reference, with a background to lipoprotein(a) biology and pathophysiology, and why it should be treated.

The Handbook deals with practical issues in measurement, provides recommendations for screening and treatment, and discusses emerging novel therapies. Case reports are a key feature to guide clinicians in their routine practice.

Supported by an Unrestricted Educational Grant from SANOFI and REGENERON.

App for iPad and iPhone

Clinician's guidelines - Dyslipidaemia & atherosclerosis

Dyslipidaemia and Atherosclerosis: Clinician's Guidelines translates recent guidelines for prevention of cardiovascular disease – the ESC/EAS Joint Guidelines for Management of Dyslipidaemia (2011) – to an accessible ready reference.

The content differentiates lipoproteins containing apolipoproteins B or A and their role in atherosclerosis.

For the clinician, the focus is on which lipids should be analysed for risk estimation, and an overview of primary, secondary and genetic causes of dyslipidaemias. The content summarises lifestyle and pharmacotherapy options for clinical management, lipid treatment targets and practical advice for treating patients.

Authored by leading experts in the field, these guidelines will be an invaluable accessible resource for both primary and secondary care clinicians.

Supported by an Unrestricted Educational Grant from SANOFI and REGENERON.

App for iPad and iPhone

 

Clinician's handbook - Triglyceride-rich lipoproteins and high-density lipoprotein in cardiometabolic disease: Therapeutics old and new.

Elevated triglyceride-rich lipoproteins (TRL), for which triglycerides are a marker, and low plasma concentrations of high-density lipoprotein cholesterol (HDL-C), often referred to as atherogenic dyslipidaemia, is a common risk factor for cardiometabolic disease, even among individuals who achieve target level of low-density lipoprotein cholesterol (LDL-C). Both are also key components of the metabolic syndrome, a pre-diabetic state. Atherogenic dyslipidaemia is also a key driver of cardiovascular risk in individuals with metabolic syndrome or diabetes.

The 2011 ESC/EAS Guidelines for Management of Dyslipidaemia include recommendations for the management of elevated triglycerides and/or low HDL-C after achievement of LDL-C goals. Despite this, management is still far from optimal.

This Handbook authored by Professors Chapman and Ginsberg on behalf of the European Atherosclerosis Society Consensus Panel, provides a unique accessible reference for clinicians. The Handbook provides a comprehensive background to HDL and TRL, and their relevance to cardiometabolic disease, and addresses the ongoing controversies surrounding HDL biology and its clinical relevance. Recommendations for clinical management of atherogenic dyslipidaemia are discussed in the context of the recent ESC/EAS Guidelines for Management of Dyslipidaemia.

The Handbook deals with practical issues in measurement, provides recommendations for treatment, and discusses emerging novel therapies. Case reports are a key feature to guide clinicians in their routine practice.

App for iPad and iPhone :: App for Android Phone

Membership Software Powered by YourMembership.com®  ::  Legal